Molecular characterization of ROCK leukemia between leukemia cells and endothelial cells in CNS leukemia

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K21176
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Hematology; Pediatrics
• Research Institution: Shimane University
• Principal Investigator: Onishi Chie 島根大学, 学術研究院医学・看護学系, 助教 (30598115)
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: FLT3-ITD / 白血病 / ROCK / FLT3阻害剤

Outline of Final Research Achievements

FLT3 inhibitor-resistant cells were generated by prolonged dose-escalation exposure to quizartinib and/or gilteritinib in FLT3-ITD+ Ba/F3 cells. Combination of Rho-kinase inhibitor, fasudil and FLT3 inhibitor (quizartinib or gilteritinib) reduced proliferation of FLT3 inhibitor-resistant FLT3-ITD+ Ba/F3 cells compared with the same cells treated with quizartinib or gilteritinib alone.

Free Research Field

血液内科

Academic Significance and Societal Importance of the Research Achievements

近年、FLT3阻害剤による白血病細胞の耐性化が問題視されている。今回の私たちの研究から、ROCK阻害剤が、FLT3-ITD陽性白血病細胞におけるFLT3阻害剤抵抗性を克服するの可能性が示唆された。